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ABSTRACT
Conflicting evidence exists as to whether there are differences between males and females in
circadian timing. The aim of the current study was to assess whether sex differences are
present in the circadian regulation of melatonin and cortisol in plasma and urine matrices
during a constant routine protocol. Thirty-two healthy individuals (16 females taking the oral
contraceptive pill (OCP)), aged 23.8 ± 3.7 (mean ± SD) years, participated. Blood (hourly) and
urine (4-hourly) samples were collected for measurement of plasma melatonin and cortisol, and
urinary 6-sulfatoxymelatonin (aMT6s) and cortisol, respectively. Data from 28 individuals (14
females) showed no significant differences in the timing of plasma and urinary circadian phase
markers between sexes. Females, however, exhibited significantly greater levels of plasma
melatonin and cortisol than males (AUC melatonin: 937 ± 104 (mean ± SEM) vs. 642 ± 47
pg/ml.h; AUC cortisol: 13581 ± 1313 vs. 7340 ± 368 mmol/L.h). Females also exhibited a
significantly higher amplitude rhythm in both hormones (melatonin: 43.8 ± 5.8 vs. 29.9 ± 2.3
pg/ml; cortisol: 241.7 ± 23.1 vs. 161.8 ± 15.9 mmol/L). Males excreted significantly more urinary
cortisol than females during the CR (519.5 ± 63.8 vs. 349.2 ± 39.3 mol) but aMT6s levels did not
differ between sexes. It was not possible to distinguish whether the elevated plasma melatonin
and cortisol levels observed in females resulted from innate sex differences or the OCP
affecting the synthetic and metabolic pathways of these hormones. The fact that the sex
differences observed in total plasma concentrations for melatonin and cortisol were not
reproduced in the urinary markers challenges their use as a proxy for plasma levels in circadian
research, especially in OCP users.
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Introduction
Diurnal rhythms observed in human physiology
and behaviour result from an interaction between
endogenous signals, originating in the circadian
timing system, and external signals from the phy-
sical environment, such as light-dark cycles, activ-
ity or food. Use of constant routine (CR) protocols
is an accepted method in human research to
remove or minimise external time cues and allow
rhythms driven only by endogenous circadian sti-
muli to be identified (Duffy and Dijk, 2002).
Melatonin and cortisol are two well-characterised
rhythmic hormones which are driven by the mas-
ter circadian clock, located in the suprachiasmatic
nuclei (SCN) of the anterior hypothalamus. In
entrained conditions, melatonin levels rise in the
evening hours, peak in the early hours of the
morning, and return to basal levels soon after
waking (Arendt and Skene, 2005). Cortisol begins
to increase in the early hours, peaks after wake
time and decreases throughout the rest of the day
(Debono et al., 2009; Weitzman et al., 1971).
As a result of being under the control of the
SCN oscillator, melatonin is the marker of
choice for circadian phase estimation, whereas
cortisol, due to being influenced by external
factors and its intrinsic variability, is less com-
monly used (Klerman et al., 2002). Dim light
melatonin onset (DLMO) is a highly utilised
marker of circadian phase, representing the
time at which melatonin levels begin to rise
(Lewy and Sack, 1989). When investigated in
both field and laboratory settings, DLMO has
been found to occur significantly earlier in
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women than men (Cain et al., 2010; Mongrain
et al., 2004; Van Reen et al., 2013). In addition,
the phase angle between DLMO and habitual
bedtime has been found to be shorter in
women (Burgess and Eastman, 2005). However,
the field settings or limited control of laboratory
conditions in many of these studies mean it is
difficult to conclude whether these results arose
due to differences in the endogenous circadian
rhythm of melatonin or from the influence of
other exogenous signals.
As well as differences in the timing of circadian
phase markers, differences in circulating melato-
nin and cortisol concentrations have been
observed between sexes. Although studies measur-
ing a single sample of cortisol, which are of limited
utility, have reported no sex differences (Kudielka
et al., 2004; Seeman et al., 2001), the use of a
morning and evening sample showed women had
a higher cortisol level in the morning, but not the
evening, compared to men (Larsson et al., 2009).
By contrast, samples taken at least every 30 min-
utes across a 24-hour sampling period revealed a
lower mean production of plasma cortisol in
females (Van Cauter et al., 1996). Moreover, Cain
et al. (2010) reported increased production of
plasma melatonin in females during their CR
study. In addition, evidence exists that the use of
the oral contraceptive pill (OCP) may affect hor-
mone levels, with reports that both melatonin and
cortisol increase with the use of OCPs (Kostoglou-
Athanassiou et al., 1998; Simunkova et al., 2008).
However, these studies lacked high resolution
sampling across 24 hours or more, thus not pro-
viding a detailed picture of melatonin and cortisol
production.
In addition to measuring circulating levels of
melatonin and cortisol, it is also possible to utilise
their urinary metabolites as circadian phase mar-
kers. Melatonin is excreted as 6-sulfatoxymelato-
nin (aMT6s) in the urine and aMT6s is a well-
established proxy measure of circulating melatonin
and circadian timing, strongly correlating with
plasma melatonin (Arendt et al., 1985; Kovacs
et al., 2000). Cortisol is excreted in the urine as a
number of metabolites along with free cortisol.
Like aMT6s, the timing of urinary cortisol
rhythms has been shown to be useful in tracking
circadian rhythms in the blind (Hack et al., 2003;
Lockley et al., 2000; Skene et al., 1999), with avail-
able research suggesting a moderate association
between plasma and urinary measures (Jung
et al., 2014). For both aMT6s and urinary cortisol
there is some evidence of sex-dependent effects
(Finken et al., 1999; Shamim et al., 2000;
Wetterberg et al., 1999), although limited sampling
points and unavailability of plasma levels for com-
parison make these sex differences difficult to
interpret.
Previously, CR protocols have been under-uti-
lised when examining sex differences in phase
markers and have been limited by their use of
plasma melatonin as a single circadian marker
(Cain et al., 2010). The aim of this study was to
investigate the timing and production of the cir-
cadian SCN clock-controlled hormones, melatonin
and cortisol, in males and females in unmasked
conditions using a CR protocol. The use of this
protocol allowed any sex differences in the endo-
genous regulation of these hormones to be char-
acterised. Additionally, through collection of
urinary aMT6s and cortisol in the same indivi-
duals and during the same protocol, we aimed to
examine whether sex differences existed in the
metabolism and excretion of melatonin and corti-
sol, allowing a novel and comprehensive assess-
ment of circadian markers in males and females
during a CR protocol.
Materials and methods
Study
Thirty two healthy participants (16 females) aged
between 19 and 33 years (23.7 ± 3.6 years; mean ±
SD) took part in the study. Two participants (one
female) were excluded from the analysis due to the
need for them to take paracetamol during the in-
laboratory period. One female participant was
excluded as blood was drawn for only the first 24
hours of the study period. One male participant
was excluded after being identified as an outlier
(> ± 2 SD from the mean) in seven variables
relating to melatonin production, timing and
excretion. Therefore, samples from 28 participants
(14 females) were included in the analysis (23.8 ±
3.7 years) (Table 1). The study was conducted
between January and August 2012.
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All study procedures were conducted at the
Surrey Clinical Research Centre (CRC).
Participant eligibility was determined by medical
and physical assessments, urine and blood analy-
sis, and sleep and health questionnaires. All parti-
cipants were non-smokers, free of existing medical
conditions, prescription medication (excluding the
OCP), and haematological abnormalities, and
showed no evidence of drug or alcohol abuse.
None had a history of shift work or travel across
two or more time zones in the preceding month.
All participants met defined criteria in four ques-
tionnaires: ≤ 5 in the Pittsburgh Sleep Quality
Index, < 10 in the Beck Depression Inventory, <
10 in the Epworth Sleepiness Scale, and not
extreme evening or morning types in the Horne–
Östberg Questionnaire. Participants had a regular
sleep-wake cycle with a bedtime between 22:00
and 01:00 h and wake time between 06:00 and
09:00 h with eight hours in bed. To be included
all females had to be takingthe OCP for contra-
ception and had to be in the active pill phase
during the in-laboratory period. Oral contracep-
tives used were one of four formulations: 30 µg
ethinylestradiol and 150 µg progestin (n = 10), 30
µg ethinylestradiol and 3000 µg progestin (n = 2),
35 µg ethinylestradiol and 250 µg progestin (n = 1)
or 0 µg ethinylestradiol and 75 µg progestin (n =
1). None of the female participants had a history of
menstrual irregularities prior to OCP use.
The study was approved by the University of
Surrey Ethics Committee and conducted in accor-
dance with the Declaration of Helsinki. The
experimental protocol of the study conformed to
international ethical standards (Portaluppi et al.,
2010). Oral and written informed consent for the
study was obtained from all participants before
any study procedures were performed.
In-laboratory session
The in-laboratory session was conducted at the
Surrey CRC. Seven days prior to entering the
CRC, participants were required to maintain a
self-selected, habitual eight-hour sleep schedule
(bedtime between 22:00 and 01:00 h) and receive
at least 15 minutes of outdoor light in the first 90
minutes of waking. These procedures were to
minimise any confounding sleep deprivation and
to stabilise the circadian clock prior to the labora-
tory study. Compliance to this schedule was mon-
itored by completion of a sleep and nap diary,
calling a time-stamped voicemail upon waking
and wearing an Actiwatch (Cambridge
Neurotechnology Ltd., Cambridge, UK). For 72
hours prior to the in-laboratory session partici-
pants were asked to refrain from alcohol, exercise,
bright light in the evening and caffeine.
The in-laboratory session was 68 hours in total,
beginning at 16:00 h on Day 1 and ending at 12:00
h on Day 4. After an adaptation night, participants
awoke at their habitual time on Day 2 into CR
conditions of dim light (< 5 lux in the direction of
gaze), maintaining a semi-recumbent posture, con-
tinual wakefulness and consuming hourly isocaloric
snacks with 100 ml water. Participants had no
knowledge of clock time during this period. The
CR continued until 23:00 h on Day 3, and was
followed by the opportunity for a recovery sleep.
Blood samples were drawn hourly from intra-
venous cannulae from 15:00 h on Day 2 until 23:00
h on Day 3. Samples were collected into lithium
heparin tubes, separated by centrifugation and the
plasma fraction stored at -20°C until analysis. All
urine passed between habitual bedtime on Day 1
and 23:00 h on Day 3 was collected. The first
collection period was 8 hours, between habitual
bedtime and wake time, the second collection per-
iod covered habitual wake time to 11:00 h on Day
2, and all subsequent collection periods were four-
hourly. Urine samples were frozen within 1 hour
of the end of the collection interval and stored at
-20°C until analysis.
Plasma melatonin and cortisol and urinary
aMT6s and cortisol were measured by radioimmu-
noassay (Stockgrand Ltd., University of Surrey,
UK) as previously described (Aldhous and
Arendt, 1988; Fraser et al., 1983; Lockley et al.,
Table 1. Baseline characteristics and habitual sleep time (mean
± SEM) of male and female participants.
Males (n = 14) Females (n = 14) p value
Age (years) 23.8 ± 1.1 23.7 ± 0.9 0.972†
Weight (kg) 76.8 ± 3.3 63.9 ± 2.2 0.003*
BMI (kg/m2) 23.8 ± 0.8 23.4 ± 0.6 0.688
Bedtime (dec.h) 23.82 ± 0.18 23.50 ± 0.16 0.188
Wake time (dec.h) 7.82 ± 0.18 7.50 ± 0.16 0.188
Horne–Östberg score 51.7 ± 1.8 53.4 ± 1.5 0.461
* Significant difference between sexes (p < 0.05). Independent t-tests, †
indicates Mann-Whitney test used. Data are mean ± SEM.
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2000; Riad-Fahmy et al., 1979). All samples from
one participant were run in the same assay and
measured in duplicate. The limit of detection for
the plasma melatonin assay was 3.9 pg/ml and
inter-assay coefficient of variations (CVs) were
22.2% at 8.2 pg/ml, 10.4% at 33.2 pg/ml, 9.3% at
88.8 pg/ml and 9.0% at 121.4 pg/ml. The limit of
detection for the aMT6s assay was 0.4 ng/ml with
inter-assay CVs of 9.2% at 2.9 ng/ml, 4.2% at 12.1
ng/ml and 2.3% at 21.1 ng/ml. The limit of detec-
tion for the plasma cortisol assay was 1.7 nmol/L
and inter-assay CVs were 11.2% at 67.7 nmol/L,
11.0% at 520.0 nmol/L and 8.7% at 884.0 nmol/L.
The limit of detection for the urinary cortisol assay
was 2.2 nmol/L with inter-assay CVs of 12.7% at
84 nmol/L, 9.5% at 156.0 nmol/L and 16.8% at
736.8 nmol/L.
Data analysis
In order to assess 24-hour rhythmicity of the hor-
mones, cosinor analysis was carried out (Minors
and Waterhouse, 1989). This analysis determined
the amplitude, acrophase and significance of fit to
a cosine curve for each individual hormone pro-
file. For each participant, all 33 hourly plasma
samples and all urine samples collected during
the CR were included in the cosinor analysis for
maximum validity of fitting.
To determine circadian phase, a number of
markers were calculated. Dim light melatonin
onset (DLMOn25%) and offset (DLMOff25%) were
defined as the time at which plasma melatonin
levels reached 25% of the maximum melatonin
values (Davies et al., 2014; Sletten et al., 2009) on
the evening on Day 2 and the morning of Day 3,
respectively. The following phase angles were cal-
culated: DLMOn25% relative to bedtime and wake
time (bedtime - DLMOn25% and DLMOn25% -
wake time, respectively).
In order to investigate the relationship between
plasma and urine concentrations of melatonin and
aMT6s and cortisol, clearance estimates were
calculated:
k½32-hour urinary excretion product
AUC ðngÞ
½32-hour plasma hormoneAUC
ðpg=ml:h ormmol=L:hÞ½body weight ðkgÞ
(where k = molecular weight of urinary excretion
product (g/mol)/molecular weight of plasma hor-
mone (g/mol))
Statistical analysis
Statistical analyses were carried out using
GraphPad Prism v6 (GraphPad Software, Inc., La
Jolla, CA). AUC was determined for each plasma
and urinary hormone across the entire protocol
and, for plasma melatonin, additionally between
DLMOn25% and DLMOff25%. Data sets were first
assessed for normality, with between sex differ-
ences in parametric and non-parametric variables
determined by a two-tailed independent Student’s
t-test and the Mann-Whitney U-test, respectively.
Correlation analysis was performed using
Pearson’s correlation coefficient, or Spearman’s
rank correlation coefficient for non-parametric
distributions. To assess sex differences across
time points, a two-way ANOVA (factors: time
and sex) was used with Sidak’s post-hoc tests on
urine and DLMOn25% corrected plasma values.
Results refer to mean ± SEM and significance
levels were set at p < 0.05.
Results
Of the 28 participants analysed, males and females
did not differ significantly in their age or BMI,
although males had significantly higher body
weight than the females (Table 1). Neither morn-
ingness-eveningness, as indicated by their Horne–
Östberg score, nor habitual sleep times differed
between sexes (bedtime range 22.50 to 01.00 dec.
h in males vs. 22.50 to 00.50 dec.h in females,
Table 1).
The amplitude of the melatonin rhythm during
Night 2 of the CR differed significantly between
men and women, with females exhibiting a higher
peak concentration (Table 2). These differences in
melatonin concentration were evident throughout
the CR; the AUC calculated over 32 hours was
significantly higher in women than men
(Table 2), with significantly elevated levels in
females between 3 and 8 hours after DLMOn25%
(Figure 1A). Season had no significant effect on
the observed sex differences (sex, p < 0.05; season
effect and sex x season interaction, p > 0.05).
4 P. J. GUNN ET AL.
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To investigate differences in phase timing
between sexes, a number of markers were com-
pared (Table 2). There were no significant differ-
ences identified between men and women in the
timing of plasma DLMOn25% or DLMOff25%, or
the duration of melatonin production between
these 25% thresholds (10.22 ± 0.22 h in males
vs. 10.38 ± 0.30 h in females, p = 0.676).
Likewise, there was no difference between males
and females in the timing of the melatonin
rhythm, with the clock time at which the acro-
phase occurred not differing significantly
between groups (Table 2). The clock times of
the DLMOn25% and the cosinor acrophase were
strongly correlated in males (r = 0.88, p < 0.0001),
females (r = 0.69, p = 0.006) and the group as a
whole (r = 0.80, p < 0.0001). The calculated phase
angles for DLMOn25% relative to bedtime and
wake time, DLMOff25% to wake time, and Tmin
to wake time did not differ significantly between
groups (Table 2).
In contrast to the plasma melatonin data, there
were no sex differences in the excretion of the
urinary metabolite aMT6s over the 32-hour CR
protocol (Table 2, Figure 1B). The discrepancy
between plasma production and urinary excretion
was not explained by a sex difference in the clear-
ance rate, which was not significantly different
between groups (Table 2). There was no evidence
of an effect of sex on the timing of melatonin
excretion, as indicated by similar aMT6s acro-
phases in men and women (Table 2). Levels of
plasma melatonin and urinary aMT6s were highly
correlated in both males (r = 0.85, p <0.0001),
females (r = 0.79, p = 0.0007) and the group as a
whole (r = 0.75, p < 0.001).
Plasma cortisol also showed significant differ-
ences between sexes (Table 3). Women produced
more cortisol than men over the 32-hour CR pro-
tocol with a higher amplitude observed in the
females. Season had no significant effect on the
observed sex differences (sex, p < 0.001; season
effect and sex x season interaction, p > 0.05). The
difference between sexes was sustained throughout
the protocol and statistically significant at 12 time
points (5-18 hours after DLMO) (Figure 2A).
These differences were particularly evident around
the acrophase of cortisol production, the timing of
which did not differ between males and females
(Table 3). These findings were reversed in the
urinary cortisol data, with males excreting signifi-
cantly more cortisol than females at a higher clear-
ance rate. However, the timing of the urinary
cortisol rhythm, like the plasma data, did not differ
between sexes (Table 3, Figure 2B). The difference
between plasma and urinary levels of cortisol was
additionally illustrated by an absence of correla-
tion between plasma and urine concentrations in
the whole group (r = -0.19, p = 0.342) and females
(r = 0.13, p = 0.670), although there was a non-
significant trend for a positive association in males
(r = 0.48, p = 0.08).
To investigate the effects of exogenous hormone
administration from OCP on plasma melatonin
and cortisol, individual rhythms in female partici-
pants were plotted according to the OCP that they
were taking (Figure 3). When the AUC for plasma
melatonin was divided into quartiles (interquartile
range: 666 to 1057 pg/ml.h), there was a trend for
a negative association with ethinylestradiol dose,
with the participant on the highest dose (35 µg/
day) in the lowest quartile (511 pg/ml.h) and the
participant on the lowest dose (0 µg/day) in the
highest quartile (1172 pg/ml.h). By contrast, when
the plasma cortisol AUCs were split into quartiles
(interquartile range: 9775 to 17348 mmol/L.h),
there was a positive association, with the partici-
pant on the highest ethinylestradiol dose in the
upper quartile (19831 mmol/L.h), and the
Table 2. Sex differences in parameters relating to melatonin
and 6-sulfatoxymelatonin timing, production and excretion.
Males (n =
14)
Females (n =
14)
p
value
Melatonin amplitude (pg/ml) 29.9 ± 2.3 43.8 ± 5.8 0.035*
32-hr melatonin AUC (pg/ml.h) 642 ± 47 937 ± 104 0.016*
DLMOn25% (dec.h) 22.01 ± 0.25 21.7 ± 0.23 0.356
DLMOff25% (dec.h) 8.23 ± 0.32 8.07 ± 0.26 0.698
DLMOn25% to bedtime phase
angle (h)
1.81 ± 0.24 1.8 ± 0.2 0.991
Wake time to DLMOn25% phase
angle (h)
14.13 ± 0.23 14.22 ± 0.19 0.766
DLMOff25% to wake time phase
angle (h)
-0.41 ± 0.29 -0.57 ± 0.27 0.690
Melatonin acrophase (dec.h) 3.36 ± 0.29 3.14 ± 0.21 0.547
32-hr aMT6s excretion (µg) 29.5 ± 2.7 32.2 ± 4.1 0.580
aMT6s acrophase (dec.h) 4.29 ± 0.33 3.72 ± 0.31 0.312†
Melatonin clearance (L/kg/h) 0.84 ± 0.05 0.78 ± 0.06 0.289
*Significant difference between sexes (p < 0.05). Independent t-tests,
†ndicates Mann-Whitney test used. Data are mean ± SEM. DLMOn25%,
dim light melatonin onset; DLMOff25%, dim light melatonin offset;
aMT6s, 6-sulfatoxymelatonin.
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participant on the lowest dose in the lowest quar-
tile (5345 mmol/L.h). There were no such trends
present when progestin dose was analysed in a
similar way.
Discussion
This study set out to assess whether sex differences
in the circadian rhythms of melatonin, cortisol and
Table 3. Sex differences in parameters relating to cortisol timing, production and excretion.
Males (n = 14) Females (n = 14) p value
32-hr cortisol AUC (mmol/L.h) 7340 ± 368 13581 ± 1313 0.0001*
Cortisol amplitude (mmol/L) 161.8 ± 15.9 241.7 ± 23.1 0.019a*
Cortisol acrophase (dec.h) 10.04 ± 0.23 9.51 ± 0.23 0.079a
Urinary cortisol acrophase (dec.h) 9.12 ± 0.32 9.04 ± 0.40 0.855
32-hr urinary cortisol excretion (mol) 519.5 ± 63.8 349.2 ± 39.3 0.031†*
Cortisol clearance (L/kg/h) 0.92 ± 0.08 0.48 ± 0.09 0.0008*
*Significant difference between sexes (p < 0.05). Independent t-tests, † indicates Mann-Whitney test used. Data are mean ± SEM.
Figure 1. Melatonin production and excretion of 6-sulfatoxymelatonin (aMT6s) in males and females measured over 32 hours during
a constant routine (CR) protocol. (A) Plasma melatonin concentrations measured at hourly intervals in males (black circles) and
females (open triangles) over 32 hours. Data are plotted relative to each person’s DLMOn25%, designated to occur at 0 h. *p < 0.05
between sexes. Two-way ANOVA with Sidak’s multiple comparisons test, time effect p < 0.0001; sex effect p < 0.05; time x sex
interaction p < 0.0001. (B) Urinary aMT6s excretion expressed per hour from eight timed collections in males (dark bars) and females
(light bars). Two-way ANOVA with Sidak’s multiple comparisons test, time effect p < 0.0001; sex effect and time x sex interaction not
significant (p > 0.05). Data are mean ± SEM, n = 14 for each group.
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their urinary excretion products were observed in
young, healthy participants under highly con-
trolled, CR conditions. Although we did not
observe any differences in timing (melatonin
onset (DLMO25%), offset (DLMOff25%) and acro-
phase), we did observe significant sex differences
in the circulating and excreted levels of melatonin
and cortisol over the 32-hour CR. The elevated
levels of both plasma melatonin and cortisol pro-
duction observed in females compared to males
were not reproduced in the urinary excretion of
aMT6s and cortisol. In fact, while there were no
differences in aMT6s production, cortisol excre-
tion was significantly higher in males, contradict-
ing the plasma results. The observed sex
differences may be endogenous and/or OCP-dri-
ven; preliminary analysis of OCP formulation
showed a potential effect of ethinylestradiol dose
on melatonin and cortisol production.
The current data demonstrated no difference in
circadian phase timing between men and women.
This is in agreement with a previous report
Figure 2. Cortisol production and excretion in males and females measured over 32 hours during a constant routine (CR) protocol.
(A) Plasma cortisol concentration measured at hourly intervals in males (black circles) and females (open triangles) over 32 hours.
Data are plotted relative to each person’s DLMOn25%, designated to occur at 0 h. *p < 0.05 between sexes at indicated time points.
Two-way ANOVA with Sidak’s multiple comparisons test, time effect p < 0.0001; sex effect p < 0.0001; time x sex interaction p <
0.0001. (B) Urinary cortisol excretion expressed per hour from eight timed collections in males (dark bars) and females (light bars).
*p < 0.05 between sexes at indicated time points. Two-way ANOVA with Sidak’s multiple comparisons test, time effect p < 0.0001;
sex effect p < 0.05; time x sex interaction not significant (p > 0.05). Data are mean ± SEM, n = 14 for each group.
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(Burgess and Fogg, 2008) but not others (Burgess
and Eastman, 2005; Cain et al., 2010; Mongrain
et al., 2004; Van Reen et al., 2013). It is unclear
why these inconsistencies in the data exist,
although some of it may be attributable to meth-
odological differences. One reason males and
females exhibited a similar DLMO in the Burgess
and Fogg (2008) study may have been that the data
were pooled from several studies with different
habituation periods to the allocated sleep sche-
dules (from three to 15 days) (Burgess and Fogg,
2008). In addition, bedtimes for men and women
were not reported and variable bedtimes could
have masked any underlying gender differences
in endogenous timing, a possibility eliminated by
the matching of participants by sleep schedule in
other studies (Cain et al., 2010; Van Reen et al.,
2013). The strict recruitment of participants in our
study, with a tightly regulated habitual bedtime
within a three-hour window, time in bed of eight
hours, and exclusion of extreme ‘early’ or ‘late’
chronotypes, meant the male and female partici-
pants did not differ significantly in their habitual
bed and wake times, but this may also have
resulted in a narrow spread of data and prevented
differences in phase from being detected. Although
not statistically significant, the comparison of tim-
ing of the plasma cortisol acrophase in our data
approached significance (p = 0.079), with women
tending to have earlier cortisol acrophase times
Figure 3. Individual plots of plasma melatonin (A) and cortisol (B) concentrations measured at hourly intervals during a constant
routine (CR) protocol in female participants according to hormone dose: 0 µg ethinylestradiol and 75 µg progestin (long-dashed line,
n = 1), 30 µg ethinylestradiol and 150 µg progestin (solid grey line, n = 10), 30 µg ethinylestradiol and 3000 µg progestin (short-
dashed line, n = 2), 35 µg ethinylestradiol and 250 µg progestin (solid black line, n = 1). Data are plotted relative to each person’s
DLMO25%, designated to occur at 0 h.
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than men. Previous studies have found women to
be more ‘morning type’ than males, have earlier
rhythms of core clock gene expression and exhibit
a shorter circadian period (Adan and Natale, 2002;
Duffy et al., 2011; Lim et al., 2013). Therefore, the
non-significant trend in our study supports these
previous data by suggesting that women tend to
have an earlier phase than men, despite selecting
similar bed and wake times.
Although no differences were detected in the
timing of melatonin rhythms (onset, offset and
acrophase), there were clear differences in the
amount of melatonin produced by male and
female participants, in agreement with a previous
study (Cain et al., 2010). The reason for elevated
plasma melatonin production in females is not
completely understood. One plausible explanation
may be differences in melatonin synthesis caused
by sex hormones; the presence of melatonin recep-
tors in human reproductive organs and evidence
of reciprocal sex hormone receptors in the pineal
gland suggest a regulatory relationship between
sex hormones and melatonin (Ekmekcioglu, 2006;
Luboshitzky et al., 1997). In addition, animal stu-
dies demonstrate a stimulatory effect of estradiol
and an inhibitory effect of testosterone on melato-
nin secretion from the pineal gland (Cardinali
et al., 1987). It is plausible that exogenous hor-
mones from the OCPs used by females in our
study may have contributed toward our findings.
Although, in contrast to the animal data, our pre-
liminary analysis suggested that increasing ethiny-
lestradiol dose may be associated with lower
plasma melatonin levels within the female group,
the lack of a non-OCP taking control group makes
drawing definitive conclusions from our results
difficult. Previous research has reported an
increase in melatonin production in OCP users
compared to non-users (Burgess and Fogg, 2008;
Kostoglou-Athanassiou et al., 1998), which could
imply that the differences in melatonin we noted
between sexes were caused by exogenous hor-
mones from the OCP in females. However, given
that the magnitude of differences in total and peak
melatonin between men and women in our study
are almost identical to a previous report where
females were not taking the OCP (Cain et al.,
2010), it is unlikely that contraceptive hormones
alone account for the differences observed between
sexes. However, despite being unable to pinpoint
the cause of the higher plasma levels of melatonin
(OCP and/or sex difference), the physiological
implications of elevated melatonin levels in
females deserve further study.
In contrast to plasma levels of melatonin, urin-
ary levels of aMT6s did not differ between men
and women. Although individual production of
melatonin and excretion of aMT6s was highly
correlated, a difference between sexes was appar-
ent when mean levels for each group were com-
pared. This was not a result of increased urine
production in males as this was remarkably similar
between groups (data not shown). Likewise, clear-
ance rate of melatonin did not differ significantly
between groups. Melatonin is metabolised by the
liver, where it is hydroxylated to 6-hydroxymela-
tonin primarily by CYP1A2, before being conju-
gated with sulfate to form aMT6s and excreted in
the urine (Ma et al., 2005). A recent study which
examined melatonin sulfation in a number of
human tissue samples found that women either
metabolised melatonin at a higher or equal rate
to men, depending on the tissue examined (Tian
et al., 2015). This supports previous findings in a
multinational study which showed a higher excre-
tion of melatonin in females compared to males
(Wetterberg et al., 1999). However, in this study,
aMT6s was not measured, only a single sample
was taken once a month over 12-16 months, and
it is not clear how many women were on the OCP,
making a comparison between these results and
ours difficult. The OCP may have influenced mel-
atonin metabolism and excretion in the females in
the present study. In the presence of ethinylestra-
diol, the activity of hydroxylation enzymes in
humans and sulfation of melatonin and 6-hydro-
xymelatonin in human liver tissue has been found
to decrease (Papagiannidou et al., 2014; Shelepova
et al., 2005), suggesting inhibition of melatonin
metabolism in females taking OCPs. Thus, in
OCP-users, a possible concomitant elevation in
melatonin synthesis, as evidenced by human and
animal studies (Burgess and Fogg, 2008; Cardinali
et al., 1987; Kostoglou-Athanassiou et al., 1998)
and inhibition of melatonin metabolism by ethi-
nylestradiol may account for elevated plasma mel-
atonin. Inhibited melatonin metabolism may also
explain why the high plasma levels observed in the
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females in the current study do not translate into
high aMT6s levels in the urine.
Similar to melatonin, plasma cortisol levels and
amplitude were significantly higher in females.
Previous studies have yielded inconsistent results
when assessing sex differences in cortisol levels
(Kudielka et al., 2004; Larsson et al., 2009;
Seeman et al., 2001). This may be due to the use
of only one or two time points to measure cortisol
when the entire, 24-hour, profile needs to be cap-
tured in order to make accurate assessments of
circadian phase and amplitude. One previous
study which measured cortisol across 24 hours,
however, showed that total cortisol levels were
higher in males than non-OCP-using females
(Van Cauter et al., 1996). The discrepancy between
these results and the current findings could be a
result of females in our study taking the OCP. It is
well-established that exogenous estrogen increases
corticosteroid binding globulin (CBG) and, there-
fore, increases total cortisol levels in the blood
(Simunkova et al., 2008). Some additional reports
suggest that free cortisol may also increase with
OCP use, likely through increased basal activation
of the hypothalamic-pituitary-adrenal-axis
(Boisseau et al., 2013; Meulenberg et al., 1987).
Indeed, the one female participant in our analysis
who was not taking estrogen but was taking a
progesterone-only pill had cortisol levels similar
to that of the male participants. The difference in
OCP formulations also likely explains the positive
trend we observed between ethinylestradiol dose
and cortisol levels (Brien, 1975; Burke, 1969).
The finding of lower urinary cortisol in females
compared to males, supported by a reduced excre-
tion rate in women, is in line with previous
reports; both free cortisol and total cortisol meta-
bolites have been found to be elevated in males
compared to females, despite there being no dif-
ferences in urinary volume (Lamb et al., 1994;
Shamim et al., 2000). Our data are somewhat
difficult to interpret since total cortisol was mea-
sured in the plasma and free cortisol in the urine.
Cortisol is metabolised primarily in the liver and
kidney, with a number of metabolites formed
depending on the enzymatic pathway entered
(Finken et al., 1999), which, along with free corti-
sol, can then be excreted in the urine. As well as
increasing levels of bound and free cortisol
(Boisseau et al., 2013; Meulenberg et al., 1987;
Simunkova et al., 2008), estrogen reduces the abil-
ity of the liver to metabolise cortisol (Sandberg
et al., 1969). The combination of an increase in
plasma bound, inactive, cortisol and a reduced rate
of metabolism is likely to be the reason that
although females had significantly higher level of
circulating cortisol, they excreted significantly less
cortisol compared to males. A previous study
which compared total plasma cortisol to urinary
cortisol expressed relative to creatinine in females
not taking the OCP (Jung et al., 2014) found a
moderate correlation between these measures (r =
0.61), similar to the magnitude, albeit non-signifi-
cant, found in the males in our study. Another
possibility is that females diverted more free corti-
sol into metabolic pathways; previous studies have
noted a difference in the activities of enzymes
related to cortisol metabolism in males and
females (Finken et al., 1999; Raven and Taylor,
1996). However, it is not possible to determine
the contribution of these different enzyme activ-
ities to the results obtained in the present study.
One strength of this study was the strict gold stan-
dard CR conditions used to investigate the endogen-
ous clock-driven component of the melatonin and
cortisol rhythms. In addition, we have been able to
comprehensively assess these rhythms with the use of
plasma and urine samples collected over an extended
period of 32 hours. This is the first time, to our
knowledge, that plasma and urine have been mea-
sured in the same individuals and during the same CR
protocol. Our results therefore offer new insight into
potential differences in the regulation, production and
metabolism of melatonin and cortisol between males
and females. The comparatively low participant num-
bers taking different OCPs, however, has prohibited
us from carrying out statistical analysis on the differ-
ent OCP data. Further analysis comparing women
taking and not taking the OCP will help to identify
sex effects resulting from exogenous hormone admin-
istration alone and those that remain due to differ-
ences in endogenously produced sex hormones.
In conclusion, no differences in circadian timing
were found between males and females during a CR
protocol. Significantly elevated levels of plasma mel-
atonin and cortisol were observed in females, and
significantly elevated urinary cortisol was detected in
males. It was not possible to distinguish the
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contribution of innate sex differences and the use of
the OCP toward these results. The loss of the
observed plasma differences in the urinary data sug-
gest that aMT6s and urinary free cortisol may not be
accurate proxy markers for plasma melatonin and
cortisol production, particularly in participants tak-
ing exogenous contraceptive hormones.
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